Eskola Olli

Kaikkonen Minna U.

Knuuti Juhani

Li Xiang-Guo.

Liljenbäck Heidi

Miner Maxwell W.G.

Palani Senthil.

Ravindran Aarthi

Roivainen Anne

Saraste Antti

Virta Jenni

Örd Tiit

Frontiers in Immunology

UTUPub

Frontiers in Immunology | www.frontiersin.Edited and reviewed by:Nick Devoogdt,Free University of Brussels, Belgium*Correspondence:Anne Roivainenanne.roivainen@utu.fiSenthil Palanipalsen@utu.fiSpecialty section:This article was submitted toInflammation,a section of the journalFrontiers in ImmunologyReceived: 23 March 2022Accepted: 28 March 2022Published: 12 April 2022Citation:Palani S, Miner MWG, Virta J,Liljenbäck H, Eskola O, Örd T,Ravindran A, Kaikkonen MU, Knuuti J,Li X-G, Saraste A and Roivainen A(2022) Corrigendum: ExploitingGlutamine Consumption inAtherosclerotic Lesions by PositronEmission Tomography Tracer (2S,4R)-4-18F-Fluoroglutamine.Front. Immunol. 13:902544.doi: 10.3389/fimmu.2022.902544CORRECTIONpublished: 12 April 2022doi: 10.3389/fimmu.2022.902544Corrigendum: Exploiting GlutamineConsumption in AtheroscleroticLesions by Positron EmissionTomography Tracer (2S,4R)-4-18F-FluoroglutamineSenthil Palani1*, Maxwell W. G. Miner1, Jenni Virta1, Heidi Liljenbäck1,2, Olli Eskola1,Tiit Örd3, Aarthi Ravindran3, Minna U. Kaikkonen3, Juhani Knuuti 1,4,5, Xiang-Guo Li1,5,Antti Saraste1,6 and Anne Roivainen1,2,4,5*1 Turku PET Centre, University of Turku, Turku, Finland, 2 Turku Center for Disease Modeling, University of Turku, Turku,Finland, 3 A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland, 4 Turku PET Centre,Turku University Hospital, Turku, Finland, 5 InFLAMES Research Flagship Center, University of Turku, Turku, Finland, 6 HeartCenter, Turku University Hospital and University of Turku, Turku, FinlandKeywords: atherosclerosis, 18F-fluoroglutamine, PET/CT, macrophages, inflammationA Corrigendum onExploiting Glutamine Consumption in Atherosclerotic Lesions by Positron EmissionTomography Tracer (2S,4R)-4-18F-FluoroglutamineBy Palani S, Miner MWG, Virta J, Liljenbäck H, Eskola O, Örd T, Ravindran A, Kaikkonen MU,Knuuti J, Li X-G, Saraste A and Roivainen A (2022) Front. Immunol. 13:821423.doi: 10.3389/fimmu.2022.821423In the original article, there was a mistake in Figure 2 as published. The Mac-3 and SLC7A7 imageson the left column were incorrectly positioned, i.e they had changed places. The corrected Figure 2appears below.The authors apologize for this error and state that this does not change the scientific conclusionsof the article in any way. The original article has been updated.Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those oftheir affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in thisarticle, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.Copyright © 2022 Palani, Miner, Virta, Liljenbäck, Eskola, Örd, Ravindran, Kaikkonen, Knuuti, Li, Saraste and Roivainen. Thisis an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distributionor reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that theoriginal publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction ispermitted which does not comply with these terms.org April 2022 | Volume 13 | Article 9025441FIGURE 2 | Expression of Mac-3 and glutamine transporters by mouse aortic plaque macrophages. Movat’s pentachrome staining of the aortic root demonstratesthat atherosclerotic plaques were composed mostly of a fibrous cap and a necrotic region. Immunostaining of adjacent sections shows that Mac-3-positivemacrophages are also positive for glutamine transporters SLC1A5, SLC3A2, and SLC7A7. Higher magnifications of the valve and plaque vessel regions are shown inthe black and red rectangular boxes, respectively. Expression of SLC1A5 is prominent in the aortic valve region but not in the vessel plaque region. Expression ofSLC3A2 is absent from the valve region but present in the vessel plaque region. Expression of SLC7A7 is clear in both the valve and vessel plaque regions. Scalebar = 200 mm; zoomed region scale bar = 50 mm.Palani et al. Corrigendum: 18F-FGln Uptake by Atherosclerotic LesionsFrontiers in Immunology | www.frontiersin.org April 2022 | Volume 13 | Article 9025442

Corrigendum: Exploiting Glutamine Consumption in Atherosclerotic Lesions by Positron Emission Tomography Tracer (2S,4R)-4-18F-Fluoroglutamine(Front. Immunol., (2022), 13, (821423), 10.3389/fimmu.2022.821423)

https://www.utupub.fi/bitstream/10024/163144/1/fimmu-13-902544.pdf

Corrigendum: Exploiting Glutamine Consumption in Atherosclerotic Lesions by Positron Emission Tomography Tracer (2S,4R)-4-18F-Fluoroglutamine(Front. Immunol., (2022), 13, (821423), 10.3389/fimmu.2022.821423)

Abstract

Similar works

Full text

Available Versions

UTUPub